cancers-logo

Journal Browser

Journal Browser

Novel Insights into Glioblastoma and Brain Metastases (2nd Edition)

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Metastasis".

Deadline for manuscript submissions: 31 July 2026 | Viewed by 515

Special Issue Editor


E-Mail Website
Guest Editor
Department of Immunotherapeutics and Biotechnology, Texas Tech University Health Sciences Center, 1718 Pine Street, Abilene, TX 79601, USA
Interests: development of phytochemicals for cancer prevention and therapeutics; targeting STAT-3; NF-kB; HER2; MCL-1; AKT/FOXO; GLI1/2; and related signaling pathways with agents such as capsaicin; piperlongumine; penfluridol; isothiocyanates; diindolylmethane; panabinostat; cucurbitacin B; and deguelin in pancreatic; ovarian; breast; melanoma; and brain cancer; drug repurposing
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is the second edition of the Special Issue “Novel Insights into Glioblastoma and Brain Metastases”, available at https://www.mdpi.com/journal/cancers/special_issues/UOW92IR7VI.

Glioblastoma is an aggressive grade IV brain tumor leading to severe fatalities globally. Moreover, several cancers lead to brain metastasis which is a major cause of mortality. Tackling these conditions has several challenges, with the most important being the blood–brain barrier (BBB) permeability. Significant research is required to overcome these challenges. With surgery and radiation therapy being the major treatment strategy for brain tumors, intensive research has also been conducted on chemotherapies. Targeted therapies are currently being developed with beneficial effects in cancers such as colorectal, breast, lung, and melanoma. Radiation therapy has also proven to be quite successful against brain metastasis. Thus, in this Special Issue, we invite you to contribute your work concerning glioblastoma, novel insights into its treatment and management, and different cancers leading to brain metastasis. This Special Issue aims to highlight all types of work, such as clinical, pre-clinical, translational, and basic research. We invite both original research articles and review articles in this Special Issue. This critical topic would appeal to a number of scientists and clinicians in the field. The articles may include (but are not limited to) treatment, management, diagnosis, clinical trials, and molecular insights for glioblastoma and brain metastasis caused by different cancers such as breast, melanoma, renal, lung, and colorectal, etc.

Prof. Dr. Sanjay K. Srivastava
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • glioblastoma
  • brain metastasis
  • surgery
  • radiation
  • chemotherapy
  • blood–brain barrier
  • immunotherapy
  • novel targets
  • oncogenes
  • tumor heterogeneity
  • drug discovery

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

28 pages, 10458 KB  
Article
Whole-Genome Sequencing Reveals a Novel GATA2 Mutation in Lower-Grade Glioma: Bioinformatics Analysis of Functional and Therapeutic Implications
by Handoko, Vincent Lau, Eka Susanto, Renindra Ananda Aman, Didik Setyo Heriyanto and Soehartati A. Gondhowiardjo
Cancers 2025, 17(20), 3338; https://doi.org/10.3390/cancers17203338 - 16 Oct 2025
Viewed by 385
Abstract
Background/Objectives: Lower-grade gliomas, particularly IDH-mutant astrocytomas, represent a distinct molecular subtype with unique therapeutic challenges. Whole-genome sequencing (WGS) plays a crucial role in uncovering genetic alterations that drive glioma pathogenesis and therapeutic resistance. This study identifies and evaluates a novel GATA2 p.Arg396Trp [...] Read more.
Background/Objectives: Lower-grade gliomas, particularly IDH-mutant astrocytomas, represent a distinct molecular subtype with unique therapeutic challenges. Whole-genome sequencing (WGS) plays a crucial role in uncovering genetic alterations that drive glioma pathogenesis and therapeutic resistance. This study identifies and evaluates a novel GATA2 p.Arg396Trp mutation in a clinical sample of lower-grade glioma, assessing its structural impact and implications for drug binding. Methods: A WHO Grade II astrocytoma specimen from a 33-year-old female patient was analyzed using WGS with Oxford Nanopore sequencing, followed by comprehensive bioinformatics processing to identify genomic variants. The GATA2 p.Arg396Trp mutation was evaluated using protein modeling, structural analysis, and pathogenicity prediction tools. Drug affinity analysis was conducted using molecular docking simulations to assess the computational impact of the mutation on drug binding. Results: The GATA2 p.Arg396Trp mutation was identified as a computationally predicted pathogenic variant, potentially disrupting protein interactions within critical functional domains. Structural analysis revealed altered binding dynamics with key anti-neoplastic agents, suggesting potential implications for therapeutic response. These findings represent computational predictions requiring experimental validation. Conclusions: Our preliminary findings suggest a potential role of the GATA2 p.Arg396Trp mutation in lower-grade glioma pathogenesis. The mutation predicted impact on transcriptional regulation and drug affinity suggests GATA2 as a possible biomarker candidate. Extensive experimental validation in larger patient cohorts is needed to establish clinical relevance and explore targeted therapeutic strategies. Full article
(This article belongs to the Special Issue Novel Insights into Glioblastoma and Brain Metastases (2nd Edition))
Show Figures

Figure 1

Back to TopTop